Liver and Bile
J Hepatol. 2023;78(1):57–66
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Background and aims: Data on the long-term persistence of hepatitis C virus (HCV) resistance-associated substitutions (RASs) after treatment with direct-acting antivirals (DAAs) are limited. This study evaluated the persistence of NS3, NS5A, and NS5B RASs for up to 5 years after the end of treatment (EOT).
Methods: The authors included samples from 678 individuals with an HCV genotype (GT) 1 or 3 infection and virologic DAA treatment failure collected in the European Resistance Database. NS3, NS5A, and NS5B were sequenced, and clinical parameters were evaluated.
Results: A total of 242 individuals with HCV GT1a (36%), 237 with GT1b (35%), and 199 (29%) with GT3 and a DAA failure were included. After protease inhibitor failure, the frequencies of NS3 RASs were 40–90% after the EOT. NS3 RASs disappeared rapidly in GT1b and GT3 after follow-up month 3 but were stable (≥ 60%) in GT1a owing to Q80K. The sofosbuvir-resistant NS5B RAS S282T was only found in individuals with GT3a. Non-nucleoside NS5B RASs were frequent in GT1 (56–80%) and decreased to 30% in GT1a but persisted in GT1b. NS5A RASs were very common in all GTs after NS5A inhibitor failure (88–95%), and even after follow-up month 24, their frequency was 65% and higher. However, RASs in GT1b had a stable course, whereas RASs in GT1a and GT3 declined slightly after follow-up month 24 (GT1a, 68%; GT1b, 95%; and GT3, 65%), mainly because of the slow decline of high-level resistant Y93H.
Conclusions: The authors found that low-to-medium level resistance-associated substitutions (RASs) persisted, whereas high-level resistant RASs disappeared over time. Different patterns of RAS persistence according to hepatitis C virus (HCV) subtype could have implications for retreatment with first-generation direct-acting antivirals and for global HCV elimination goals.